Verona Pharma Plc Stock London S.E.
Equities
GB00B06GSH43
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
Sales 2024 * | 15.35M 19.25M | Sales 2025 * | 103M 130M | Capitalization | 1.01B 1.27B |
---|---|---|---|---|---|
Net income 2024 * | -83M -104M | Net income 2025 * | -38M -47.67M | EV / Sales 2024 * | 54 x |
Net cash position 2024 * | 184M 231M | Net cash position 2025 * | 146M 184M | EV / Sales 2025 * | 8.38 x |
P/E ratio 2024 * |
-24.5
x | P/E ratio 2025 * |
-82.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma Plc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
1st Jan change | Capi. | |
---|---|---|
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |